332
Canadian Family Physician
•
Le Médecin de famille canadien
|
VOL 60: APRIL • AVRIL 2014
Clinical Review |
Bisphosphonates for treatment of osteoporosis
Family Medicine at the University of British Columbia. Dr Olszynski works in
the Department of Medicine at the University of Saskatchewan in Saskatoon.
Dr Ste-Marie works in the Department of Medicine at the University of
Montreal in Quebec. Dr Adachi works in the Department of Medicine at
McMaster University.
Acknowledgment
This manuscript was supported and endorsed by Osteoporosis Canada.
Contributors
All authors contributed to the design and conduct of this review and contributed
to, edited, and approved the final manuscript for submission.
Competing interests
Dr Brown has received research grants, consulting fees, or speakers’ bureau
fees from Abbott, Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis,
Pfizer, Roche, Sanofi-Aventis, Servier, Takeda, and Warner Chilcott. Dr Morin
has received research grants or consultant or speaker fees from Amgen, Eli
Lilly, Merck, and Novartis. Dr Leslie has received speaker’s fees from, received
research grants from, or participated on advisory boards for Amgen, Genzyme,
and Novartis. Dr Papaioannou has been a speaker or consultant for Amgen,
Eli Lilly, Merck, Novartis, and Warner Chilcott. Dr Cheung has been a speaker
or consultant for Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcott. Dr
Davison has been a speaker or consultant for Amgen, Merck, Novartis, and
Warner Chilcott. Dr Goltzman has been a consultant for Amgen, Eli Lilly,
Merck, and Novartis. Dr Hanley has been a speaker or consultant for Amgen,
Eli Lilly, Novartis, NPS Pharmaceuticals, Servier, and Warner Chilcott. Dr
Hodsman has been a speaker or consultant for Amgen, Novartis Canada, Shire
Pharmaceuticals Canada, and Warner Chilcott Canada. Dr Josse has been a
speaker or consultant for Novartis, Sanofi-Aventis, Servier, and Warner Chilcott.
Dr Jovaisas has been a speaker and consultant for Novartis. Dr Juby has been
a speaker or consultant for Amgen, Eli Lilly, Merck, Novartis, and Warner
Chilcott. Dr Kaiser has been a speaker or consultant for Amgen, Eli Lilly, Merck,
Novartis, and Warner Chilcott. Dr Karaplis has been a speaker and consultant
for Novartis. Dr Kendler has received research grants from, been a speaker or
consultant for, or participated on advisory boards for Amgen, Eli Lilly, Johnson
& Johnson, Merck, Novartis, Roche, Pfizer, and Warner Chilcott. Dr Khan has
been a speaker or consultant for Amgen, Merck, and NPS Pharmaceuticals. Dr
Olszynski has been a speaker or consultant for Amgen, Merck, Novartis, and
Warner Chilcott. Dr Ste-Marie has been a speaker or consultant for Amgen, Eli
Lilly, Merck, Novartis, and Warner Chilcott. Dr Adachi has been a speaker or
consultant for Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche,
Sanofi-Aventis, and Warner Chilcott.
Correspondence
Dr Kenneth Davison, 2086 Byron St, Victoria, BC V8R 1L9;
References
1. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman A, et
al. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis
Rheum 2006;36(1):22-31.
2. Papaioannou A, Wiktorowicz ME, Adachi JD, Goeree R, Papadimitropoulos E,
Bedard M. Mortality, independence in living, and re-fracture one year following
hip fracture in Canadians. J Obstet Gynaecol Can 2000;22(8):591-7.
3. Papaioannou A, Adachi JD, Parkinson W, Stephenson G, Bedard M. Lengthy hos-
pitalization associated with vertebral fractures despite control for comorbid con-
ditions. Osteoporos Int 2001;12(10):870-4.
4. Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, et al. The
burden of prevalent fractures on health-related quality of life in postmenopausal
women with osteoporosis: the IMOF study. J Rheumatol 2007;34(7):1551-60.
5. Pande I, Scott DL, O’Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life,
morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis
2006;65(1):87-92.
6. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T,
Pickard L, et al. Relation between fractures and mortality: results from the
Canadian Multicentre Osteoporosis Study. CMAJ 2009;181(5):265-71.
7. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K,
Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older
women and men. Ann Intern Med 2010;152(6):380-90.
8. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al.
2010 clinical practice guidelines for the diagnosis and management of osteopo-
rosis in Canada: summary. CMAJ 2010;182(17):1864-73.
9. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, et al.
Oral bisphosphonates are associated with reduced mortality after hip fracture.
Osteoporos Int 2011;22(3):983-91.
10. Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, et
al. Oral bisphosphonates are associated with reduced mortality in frail older peo-
ple: a prospective five-year study. Osteoporos Int 2011;22(9):2551-6.
11. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et
al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J
Med 2007;357:1799-809.
12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et
al. Randomised trial of effect of alendronate on risk of fracture in women with
existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet
1996;348(9041):1535-41.
13. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E,
Musliner TA, et al. Effect of alendronate on risk of fracture in women with
low bone density but without vertebral fractures: results from the Fracture
Intervention Trial. JAMA 1998;280(24):2077-82.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-
yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J
Med 2007;356:1809-22.
15. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect
of risedronate on the risk of hip fracture in elderly women. Hip Intervention
Program Study Group. N Engl J Med 2001;344:333-40.
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et
al. Effects of risedronate treatment on vertebral and nonvertebral fractures
in women with postmenopausal osteoporosis: a randomized controlled
trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA
1999;282(14):1344-52.
17. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the
jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral
Maxillofac Surg 2004;62(5):527-34.
18. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and
risk of incident atrial fibrillation in women. Arch Intern Med 2008;168(8):826-31.
19. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N
Engl J Med 2009;360:89-90.
20. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely
suppressed bone turnover: a potential complication of alendronate therapy. J Clin
Endocrinol Metab 2005;90(3):1294-301.
21. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures
during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010;72(2):161-8.
22. Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, et al.
Construction and validation of a simplified fracture risk assessment tool for
Canadian women and men: results from the CaMos and Manitoba cohorts.
Osteoporos Int 2011;22(6):1873-83.
23. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphos-
phonates: similarities and differences and their potential influence on clinical
efficacy. Osteoporos Int 2008;19(6):733-59.
24. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of
bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
Clin Pharmacokinet 2005;44(6):551-70.
25. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al.
Significant differential effects of alendronate, estrogen, or combination therapy
on the rate of bone loss after discontinuation of treatment of postmenopausal
osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern
Med 2002;137(11):875-83.
26. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al.
Effect of denosumab on bone density and turnover in postmenopausal women
with low bone mass after long-term continued, discontinued, and restarting of
therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-9.
27. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1
year of discontinuation of raloxifene or estrogen therapy on bone mineral
density after 5 years of treatment in healthy postmenopausal women. Bone
2002;30(4):599-603.
28. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients.
Osteoporos Int 2000;11(6):533-6.
29. Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and
fracture reduction among US women aged 45 years and older, 2001-2008. J Bone
Miner Res 2011;26(1):3-11.
30. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force
of the American Society for Bone and Mineral Research. J Bone Miner Res
2007;22(10):1479-91.
31. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of
the jaw. Osteoporos Int 2011;22(12):2951-61.
32. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al.
Denosumab compared with zoledronic acid for the treatment of bone
metastases in patients with advanced breast cancer: a randomized, double-blind
study. J Clin Oncol 2010;28(35):5132-9.
33. Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO, et al.
Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral
and maxillofacial surgeons. J Rheumatol 2011;38(7):1396-402.
34. Malden N, Lopes V. An epidemiological study of alendronate-related osteone-
crosis of the jaws. A case series from the south-east of Scotland with attention
given to case definition and prevalence. J Bone Miner Metab 2012;30(2):171-82.
35. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, et
al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like
lesions in rice rats (oryzomys palustris) with periodontitis. J Bone Miner Res
2012;27(10):2130-43.
36. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al.
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task
force of the American Society for Bone and Mineral Research. J Bone Miner Res
2010;25(11):2267-94.
37. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy
femoral shaft fractures associated with alendronate use. J Orthop Trauma
2008;22:346-50.
38. Dell R, Greene D, Ott SM, Silverman S, Eisemon E, Funahashi T, et al. A retro-
spective analysis of all atypical femur fractures seen in a large California HMO
from the years 2007 to 2009 [abstract]. J Bone Miner Res 2010:25.
39. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE.
Atypical fractures and bisphosphonate therapy: a cohort study of patients with